Nemaura Medical (Nasdaq:NMRD) announced that it brought in $6.5 million in non-dilutive funding through a clean debt facility.
The Loughborough, England-based company said its debt facility features no warrants or convertible elements. It comes from the company’s existing lender.
Nemaura Medical did not list an intended use for the added funds. The company develops daily, non-invasive, disposable, wearable glucose sensors. It also offers digital diabetes management tools and earlier this year added CGM-guided insulin dose titration to its offerings.
Get the full story at our sister site, Drug Delivery Business News.